BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Mapping and Targeting of Oncoprotein Signaling Networks
DTSTART:20170516T121500
DTEND:20170516T131500
DTSTAMP:20260506T195423Z
UID:f6fd48662acf7e61d7c7fb7ba9565115247c7de7f26641ac2bdc6d18
CATEGORIES:Conferences - Seminars
DESCRIPTION:Dr Oliver Hantschel\, EPFL\nBio: Oliver Hantschel studied bioc
 hemistry at the University of Regensburg and at Rockefeller University in 
 New York City. He received his PhD in 2004 from the European Molecular Bio
 logy Laboratory in Heidelberg and did postdoctoral work with Giulio Supert
 i-Furga at the Research Center for Molecular Medicine of the Austrian Acad
 emy of Sciences in Vienna. In 2011\, he was nominated Tenure Track Assista
 nt Professor at the EPFL School of Life Sciences and was awarded the first
  'ISREC Foundation Chair in Translational Oncology'.\nOncogenic signaling
  networks display a remarkable degree of plasticity. Despite only a limit
 ed number of alterations in oncogenes and tumor suppressor genes in most 
 tumours\, the majority of targeted anti-cancer therapeutics does not stro
 ngly improve the survival of cancer patients and suffers from the rapid d
 evelopment of resistance.\n\nWork in my lab focuses on providing a detail
 ed molecular understanding of how key oncoproteins reprogram cellular s
 ignaling networks and how targeted inhibitors perturb them. We use struc
 tural biology and protein biochemistry to understand the structure and re
 gulation of key kinase oncoproteins at the molecular level\, as well as s
 tate-of-the-are quantitative proteomics methods to map their cellular pro
 tein interaction- and phosphoproteome networks.\n\nOur aim is to identify
  innovative and unconventional ways to selectively interfere with oncopro
 tein signaling with engineered proteins or small molecule inhibitors. Ov
 er the past years\, we have established the use of small engineered anti
 body mimics\, termed monobodies\, to potently and selectively target intr
 acellular protein-protein interactions of central oncoproteins. We are de
 veloping methods to deliver monobody proteins into tumor cells and to es
 tablish them as novel intracellular protein-based therapeutics.
LOCATION:SV 1717 https://plan.epfl.ch/?room==SV%201717
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR